Global Advanced Pharmaceuticals
Global Advanced Pharmaceuticals, often referred to as GAP, is a leading player in the pharmaceutical industry, headquartered in Egypt (EG). Established in 2006, the company has made significant strides in the development and manufacturing of high-quality generic and innovative medicines, primarily serving markets across the Middle East and North Africa. GAP's core offerings include a diverse range of therapeutic products, with a strong emphasis on quality and affordability. The company is renowned for its commitment to research and development, ensuring that its products meet stringent international standards. With a robust market position, Global Advanced Pharmaceuticals has achieved notable milestones, including numerous certifications and partnerships that enhance its reputation as a trusted provider in the healthcare sector.
DitchCarbon Score
How does Global Advanced Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Global Advanced Pharmaceuticals's score of 0 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Global Advanced Pharmaceuticals's reported carbon emissions
Global Advanced Pharmaceuticals, headquartered in Egypt (EG), currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions data to analyse. In the absence of concrete emissions statistics, it is important to note that the company has not outlined any specific reduction targets or climate commitments. This lack of information suggests that Global Advanced Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Global Advanced Pharmaceuticals to establish clear climate commitments and reduction initiatives to align with global efforts in combating climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Global Advanced Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
